Pure Financial Advisors LLC Sells 1,539 Shares of Johnson & Johnson (NYSE:JNJ)

Pure Financial Advisors LLC lowered its stake in Johnson & Johnson (NYSE:JNJ) by 8.1% during the 4th quarter, Holdings Channel reports. The institutional investor owned 17,431 shares of the company’s stock after selling 1,539 shares during the quarter. Pure Financial Advisors LLC’s holdings in Johnson & Johnson were worth $2,521,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Tudor Financial Inc. raised its stake in Johnson & Johnson by 17.5% during the 4th quarter. Tudor Financial Inc. now owns 6,436 shares of the company’s stock worth $930,000 after acquiring an additional 959 shares during the period. Priebe Wealth Holdings LLC increased its stake in shares of Johnson & Johnson by 39.3% in the fourth quarter. Priebe Wealth Holdings LLC now owns 1,817 shares of the company’s stock worth $263,000 after purchasing an additional 513 shares in the last quarter. Hoese & Co LLP raised its position in shares of Johnson & Johnson by 15.6% during the 4th quarter. Hoese & Co LLP now owns 2,502 shares of the company’s stock valued at $362,000 after purchasing an additional 338 shares during the period. Wealthquest Corp lifted its stake in shares of Johnson & Johnson by 1.3% during the 4th quarter. Wealthquest Corp now owns 9,277 shares of the company’s stock valued at $1,342,000 after buying an additional 115 shares in the last quarter. Finally, Amplius Wealth Advisors LLC boosted its holdings in Johnson & Johnson by 16.1% in the 4th quarter. Amplius Wealth Advisors LLC now owns 5,234 shares of the company’s stock worth $757,000 after buying an additional 727 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Johnson & Johnson

In related news, Director Mark A. Weinberger bought 1,000 shares of Johnson & Johnson stock in a transaction dated Thursday, December 12th. The shares were acquired at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the transaction, the director now owns 1,000 shares in the company, valued at $147,220. The trade was a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of NYSE:JNJ opened at $145.39 on Thursday. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $168.85. The company has a market capitalization of $350.04 billion, a price-to-earnings ratio of 21.04, a PEG ratio of 2.50 and a beta of 0.51. The firm’s 50-day moving average is $148.26 and its 200 day moving average is $156.12.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The firm had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22,438,500 billion. During the same period in the prior year, the business posted $2.29 earnings per share. The company’s revenue for the quarter was up 5.3% on a year-over-year basis. Research analysts predict that Johnson & Johnson will post 9.95 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.41%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is currently 71.78%.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on JNJ shares. Bank of America lowered their price objective on Johnson & Johnson from $166.00 to $160.00 and set a “neutral” rating on the stock in a research report on Friday, January 17th. Wells Fargo & Company boosted their price target on Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. Royal Bank of Canada increased their price objective on shares of Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a report on Wednesday, October 16th. Morgan Stanley boosted their target price on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. Finally, Guggenheim raised their target price on shares of Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a research note on Wednesday, November 6th. Eight research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $173.27.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.